Full-Time
Area Manager
Specialty Northeast
Posted on 11/30/2025
CSL
10,001+ employees
Develops and delivers biotherapies and vaccines
No salary listed
Manchester, NH, USA
In Person
Regular travel required; weekends may be needed for select customer or corporate meetings/events.
 Sales & Account Management (2) |
|---|
| , |
- Bachelor degree in a scientific or business field
- Minimum of five years’ pharmaceutical sales or required relevant experience
- Demonstrated success with field sales and market share growth
- Knowledge of the pharmaceutical market and regulations
- Promote products and increase usage of products to select call points, including Health Care Professionals, hospitals, hemophilia treatment centers, patient support groups, distributors and/or specialty pharmacies. Develops customer advocates for promoted products.
- Responsible for the development of new accounts and the growth of existing accounts through solid customer relationships, communication of technical product and disease state information, and effective territory management skills.
- Develop and implement territory business plans consistent with corporate direction designed to achieve/exceed territory sales targets. Appropriate knowledge of product features and benefits, competitive products and programs and distribution channels.
- Implement key marketing programs to increase market share of key promoted products.
- Maintain proper call frequency with assigned targets and update as needed to assure time is aligned with current product focus.
- Stay abreast of current clinical technical literature from medical journals and other information sources.
- Implement CSL selling model (PS2) with effective opening, probing, listening, and closing skills on customer calls.
- Actively work with patient support groups where appropriate, following CSL Behring SOP’s.
- Stay abreast of pertinent marketplace issues and opportunities and effectively communicates them to manager.
- Represent CSL Behring at local customer meetings as appropriate to increase exposure of CSL Behring products and services.
- Regular travel required which may include weekends for select customer or corporate meeting and events.
CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parkville, Australia
Founded
1916
Simplify's Take
What believers are saying
- HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
- KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
- VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.
What critics are saying
- Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
- Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
- Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.
What makes CSL unique
- CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
- CSL Seqirus dominates influenza vaccines with global production scale.
- CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Company News
In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.
Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...
Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.
Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022
Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients